Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E148.16 EPS (ttm)1.23 Insider Own0.70% Shs Outstand225.32M Perf Week3.16%
Market Cap41.06B Forward P/E32.72 EPS next Y5.57 Insider Trans-7.73% Shs Float224.50M Perf Month3.20%
Income231.10M PEG7.49 EPS next Q1.10 Inst Own98.30% Short Float2.88% Perf Quarter1.35%
Sales2.50B P/S16.41 EPS this Y156.70% Inst Trans1.61% Short Ratio3.81 Perf Half Y11.23%
Book/sh36.48 P/B5.00 EPS next Y12.03% ROA2.60% Target Price218.13 Perf Year-5.46%
Cash/sh6.47 P/C28.15 EPS next 5Y19.78% ROE3.90% 52W Range142.02 - 208.88 Perf YTD-1.51%
Dividend- P/FCF80.72 EPS past 5Y14.90% ROI19.50% 52W High-12.75% Beta0.79
Dividend %- Quick Ratio2.90 Sales past 5Y42.00% Gross Margin91.00% 52W Low28.32% ATR5.44
Employees2273 Current Ratio3.20 Sales Q/Q20.10% Oper. Margin25.70% RSI (14)67.41 Volatility2.68% 3.03%
OptionableYes Debt/Eq0.42 EPS Q/Q-192.00% Profit Margin9.20% Rel Volume0.67 Prev Close177.80
ShortableYes LT Debt/Eq0.40 EarningsOct 29 BMO Payout0.00% Avg Volume1.70M Price182.24
Recom1.80 SMA204.90% SMA509.74% SMA2003.29% Volume1,154,500 Change2.50%
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-14-15Downgrade Barclays Overweight → Equal Weight $220 → $205
Sep-01-15Initiated Raymond James Strong Buy $225
Jul-31-15Reiterated UBS Buy $220 → $223
Jul-31-15Reiterated Stifel Buy $239 → $257
Jul-31-15Reiterated Brean Capital Buy $213 → $221
Jul-27-15Resumed JP Morgan Overweight
May-07-15Upgrade Nomura Neutral → Buy
May-07-15Reiterated Brean Capital Buy $215 → $213
Jan-30-15Reiterated Stifel Buy $230 → $236
Jan-08-15Reiterated UBS Buy $220 → $213
Apr-25-14Reiterated Stifel Buy $219 → $220
Mar-11-14Reiterated UBS Buy $185 → $202
Mar-11-14Reiterated Stifel Buy $207 → $219
Mar-06-14Reiterated Barclays Overweight $181 → $193
Feb-10-14Reiterated Deutsche Bank Buy $125 → $205
Jan-31-14Reiterated Stifel Buy $138 → $207
Jan-31-14Reiterated Canaccord Genuity Buy $161 → $200
Jan-31-14Reiterated Barclays Overweight $141 → $181
Jan-30-14Reiterated Brean Capital Buy $142 → $200
Nov-25-15 09:53AM  EXCLUSIVE: FBB's Mike Bailey On Pfizer-Allergan Deal, Taxes, Rate Hike And Biotech Picks
Nov-24-15 12:03PM  3 Under-the-Radar Stocks That Won't Stay Ignored for Long at TheStreet
Nov-23-15 02:41PM  Is JD.Com Inc (ADR) (JD) A Good Stock To Buy? at Insider Monkey
Nov-22-15 07:42AM  3 Biotech Stocks to Buy in December at Motley Fool
Nov-21-15 12:01AM  [$$] Biotech's Biggest Battle at
Nov-20-15 10:44AM  Hedge Funds Are Dumping Delta Air Lines, Inc. (DAL) at Insider Monkey
Nov-19-15 10:00AM  Alexion to Highlight Robust Rare Disease Pipeline at Investor Day Business Wire
Nov-16-15 01:43PM  These Biotech Stocks May Start Paying Dividends in 2016 at Motley Fool
Nov-13-15 12:30PM  Mariner Investment Groups Top Biotech Stock Picks For Q4 at Insider Monkey
Nov-12-15 05:33AM  Germany, U.S. in hot pursuit of "messenger" drug molecules
Nov-11-15 03:38PM  A Duo of Catalysts Sends Alexion Pharmaceuticals 13% Higher in October at Motley Fool
Nov-10-15 09:40AM  3 Beaten-Down Biotech Stocks to Buy Now at Kiplinger
08:05AM  Vertex Reported Its 3Q15 Earnings: Stock Rose 5%
07:05AM  Buy Amgen's Healthy Dividend, Hold for Its Growth Prescription at TheStreet
Nov-09-15 05:24AM  Amgen on the hunt for potential $10bn deal at Financial Times
Nov-07-15 12:30PM  Long-Term Follow-up Study Presented at ASN 2015 Supports Effectiveness of Soliris® (eculizumab) in Preventing Thrombotic Microangiopathy (TMA) Events in Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Business Wire
11:22AM  Biotech Sees Better-than-Expected Earnings: ETFs in Focus
Nov-05-15 04:15PM  Researchers to Present Data on Enhancing the Understanding of PNH and aHUS and Underscoring the Effectiveness of Soliris® (eculizumab) Treatment at ASH 2015 Annual Meeting Business Wire
Nov-04-15 10:48AM  U.S. Justice Department Investigating Alexion Pharmaceuticals at The Wall Street Journal
Nov-02-15 04:45PM  ALEXION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
12:15PM  Dyax is another Massachusetts biotech that can trace its success to Genzyme at
Nov-01-15 01:20PM  3 Biotech Stocks to Buy in November at Motley Fool
Oct-30-15 08:19AM  Why biotech could be on the verge of a rebound
12:54AM  Edited Transcript of ALXN earnings conference call or presentation 29-Oct-15 2:00pm GMT
Oct-29-15 04:47PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
12:40PM  Alexion Beats on Earnings in Q3 but Misses on Revenues
07:59AM  Alexion (ALXN) Beats on Q3 Earnings, Revises Outlook
07:58AM  [$$] Alexion Pharmaceuticals Reports Loss On Tax Hit at The Wall Street Journal
07:07AM  Q3 2015 Alexion Pharmaceuticals Inc Earnings Release - Before Market Open
06:46AM  Street reacts to Fed, looks to GDP and earnings at CNBC
06:41AM  Alexion reports 3Q loss
06:30AM  Alexion Reports Third Quarter 2015 Results Business Wire
Oct-28-15 08:50PM  Fed turns up heat on hike just in time for weak GDP at CNBC
Oct-27-15 04:40PM  Alexion (ALXN) to Report Q3 Earnings: What to Expect?
01:25PM  Alexion Pharmaceuticals, Inc. Value Analysis (NASDAQ:ALXN) : October 27, 2015
07:19AM  Biotech ETFs: Buy, Buy, Buy?
Oct-26-15 05:59PM  Alexion Pharmaceuticals Nabs an Approval, Wall Street Not Impressed at Motley Fool
12:47PM  Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : October 26, 2015
09:41AM  Gilead Sciences Leads the Large-Cap Stocks
Oct-25-15 09:20AM  3 Top Stocks to Buy for Your Kids/Grandkids at Motley Fool
Oct-23-15 07:20PM  Lightning Round: Stay away from this group now at CNBC
04:48PM  Friday's After Hours Movers: Alexion Pharma Resumes Trading Following Halt
04:28PM  FDA Clears Alexion's Metabolic Disorder Drug at The Wall Street Journal
03:48PM  FDA Approves Strensiq (asfotase alfa) for Treatment of Patients with Perinatal-, Infantile- and Juvenile-Onset Hypophosphatasia (HPP) Business Wire
03:46PM  Alexion Wins U.S. Approval for Drug for Rare Bone Disease at Bloomberg
Oct-20-15 04:30PM  Ultragenyx (RARE) Reports Positive Interim Data on UX007
10:05AM  Q3 Worst for Biotech in 7 Years: Which Large Cap Leaders to Buy Now at 24/7 Wall St.
Oct-19-15 10:02AM  Cowen: In Biotech Earnings We Trust
Oct-18-15 01:02PM  3 Biotechs Growing Faster Than Apple at Motley Fool
Oct-16-15 11:07AM  Alexion Drove IBBs Top Ten Performance
Oct-13-15 04:30PM  Alexion (ALXN) Presents Positive 5-Year Data on Strensiq
10:56AM  Biotech Stocks Better Beat Earnings ForecastsOr Else at
Oct-12-15 06:30PM  Significant Improvements in Skeletal Mineralization and Physical Function Observed in Children with Hypophosphatasia (HPP) Treated With Strensiq (asfotase alfa) Sustained for at least Five Years Business Wire
10:00AM  Alexion Pharmaceuticals to Report Third Quarter 2015 Results on Thursday, October 29, 2015 Business Wire
Oct-08-15 05:08PM  Newly listed Pure Storage under pressure at Financial Times
Oct-07-15 10:08AM  IBBs Top Ten Stocks Outperformed with Gains of 4.31%
08:40AM  Why Merrill Lynch Now Favors Large Cap Leaders in Biotech at 24/7 Wall St.
Oct-06-15 12:44PM  Bluebird Bio: A Buying Opportunity in Biotech, says Morgan Stanley at
Oct-05-15 12:26PM  Biotech: 'Significant Absolute Upside' at
Oct-02-15 06:37PM  Wall St. Changes Tone; Stocks Rise In Strong Trade +5.23%
04:54PM  Gilead, Valeant Downgraded; IBM, Dunkin' PTs Cut at Investor's Business Daily
04:15PM  Alexion Announces Presentations at ASN 2015, Including a Long-Term Follow-Up Study of Soliris® (eculizumab) for the Prevention of Thrombotic Microangiopathy (TMA) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Business Wire
12:42PM  Alexion, Vertex Steal Mo Stanley's Eyes From Gilead at Investor's Business Daily
12:32PM  Morgan Stanley Says These 9 Health Care Stocks Are Best-Positioned, Despite Rising Drug Prices at TheStreet
12:28PM  Why Morgan Stanley Downgraded Gilead, Valeant & Regeneron at
08:51AM  Analysts' Actions -- Google, Gilead, AIG and More at TheStreet
08:45AM  Top Analyst Upgrades and Downgrades: AIG, Facebook, Gilead, Google, Regeneron, Twitter, Valeant, Vertex and More at 24/7 Wall St.
Oct-01-15 11:02AM  Alexion Pharmaceuticals, Inc. Earnings Q2, 2015
10:22AM  Biotech: Out of the Ashes at
12:06AM  Alkermes and Incyte Outperform in Large-Cap Space
Sep-29-15 03:21PM  Biotech Stocks Took a Beating on September 25
09:15AM  Healthcare Sector Stocks under Review - Celldex Therapeutics, Alexion Pharmaceuticals, Advaxis, BioDelivery Sciences and Cytori Therapeutics PR Newswire
Sep-27-15 07:00PM  Orphan drugs become big business at Financial Times
07:00PM  High healthcare prices force payers to find ways to cut their bills at Financial Times
07:00PM  Genomic advance lifts hopes of patients with rare diseases at Financial Times
Sep-26-15 09:25AM  How the Top Biotechs Handled the Valuation Shock at 24/7 Wall St.
Sep-25-15 09:07AM  Industrials Save Ivy European Opportunities Fund in August 2015
Sep-24-15 10:56AM  Oppenheimer Is Buying Alexion Pharma On Weakness
09:55AM  Why Oppenheimer Says Alexion Is a Cheap Buy Now at 24/7 Wall St.
Sep-23-15 12:40PM  No, The Government Won't Regulate Drug Prices Any Time Soon: Morgan Stanley at
Sep-22-15 07:51AM  Turing's Drug Price Gouging Gives Politicians A Gift And Biotech A Perhaps Enduring Headache at Forbes
07:51AM  The 5 Lessons From A 5000 Percent Drug Price Increase at Forbes
Sep-21-15 06:31PM  Clinton pledge on drug prices knocks $15bn off biotechs at Financial Times
01:38PM  Hillary Clinton Tweet Sends Biotech Stocks Tumbling at The Wall Street Journal
01:21PM  Mallinckrodt, Merck, Biogen: What's Moving Markets
12:45PM  The Next Biotech Giant Has Arrived
Sep-19-15 01:07PM  3 Triple-Digit Biotech Stocks That Are Worth Every Penny at Motley Fool
Sep-18-15 01:57PM  3 Biotech Stocks That Can Upgrade Your Portfolio at Motley Fool
Sep-16-15 05:27PM  Alexion Announces Presentations at 2015 American Society for Bone and Mineral Research Annual Meeting, Including New Data on Strensiq (asfotase alfa) in Children with Hypophosphatasia (HPP) Treated for Five Years Business Wire
Sep-14-15 01:57PM  Alexion Falls 2.8% on Barclays Downgrade at
09:42AM  Is The Superiority Of Entresto Just An Illusion? at Forbes
09:01AM  Not So Fast, Alexion Investors
08:57AM  Analysts' Actions -- Marvell, Dow Chemical, Other Calls at TheStreet
08:44AM  Alibaba, Marvell Tech Price Targets Cut; Kroger Upped at Investor's Business Daily
Sep-10-15 11:53AM  Yes, Biotech Stocks are CheapKind Of at
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Tetraphase, Geron, Alexion and ACADIA
Sep-09-15 05:00PM  New England Journal of Medicine (NEJM) Publishes Pivotal Phase 3 Data on Kanuma (sebelipase alfa) in Children and Adults with Lysosomal Acid Lipase Deficiency (LAL-D) Business Wire
10:00AM  Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Sep-07-15 11:20AM  Alexion's Kanuma FDA Action Date Delayed by Three Months
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica. In addition, it develops Asfotase alfa, a targeted enzyme replacement therapy that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1007, a novel humanized antibody in Phase II clinical trials for the treatment of anti-phospholipid syndrome and graft versus host disease; and cPMP (ALXN 1101) that is in Phase II trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thiel CarstenEVP, Chief Commercial OfficerNov 10Sale173.343,000520,02028,018Nov 12 06:25 PM
PARVEN ALVIN SDirectorNov 02Sale178.73895159,9634,645Nov 04 05:29 PM
Islam SaqibEVP, Chief Strat & Port. Off.Nov 02Sale180.00975175,50037,335Nov 04 05:29 PM
BELL LEONARDDirectorNov 02Sale180.1235,0006,304,200919,088Nov 04 05:29 PM
Islam SaqibEVP, Chief Strat & Port. Off.Oct 26Sale168.441,558262,43038,310Oct 29 05:17 PM
Thiel CarstenSVP, EMEA & Asia PacificSep 10Sale169.18812137,37129,018Sep 10 08:45 PM
Miller EdwardSVP, Chief Compliance OfficerSep 09Sale179.5536665,7156,464Sep 10 08:45 PM
BELL LEONARDDirectorSep 09Sale180.101,050189,105919,088Sep 10 08:46 PM
O'Neill JulieEVP. Global OperationsSep 02Sale171.76647111,12921,443Sep 10 08:46 PM
Carmichael ClareEVP, Chief HR OfficerSep 01Sale168.6230551,42927,156Sep 03 07:08 PM
Hallal DavidCEOAug 07Sale190.0132962,513143,187Aug 11 05:53 PM
Carmichael ClareEVP, Chief HR OfficerAug 07Sale190.0116330,97227,461Aug 11 05:53 PM
Moriarty John BEVP & General CounselAug 07Sale190.0113525,65142,283Aug 11 05:53 PM
BELL LEONARDDirectorAug 07Sale190.011,003190,580919,088Aug 11 05:53 PM
Moriarty John BEVP & General CounselAug 05Option Exercise92.6520,0001,853,00042,428Aug 05 06:08 PM
Moriarty John BEVP & General CounselAug 05Sale198.4410,0101,986,37732,418Aug 05 06:08 PM
Carmichael ClareEVP, Chief HR OfficerAug 04Sale196.5218536,35627,624Aug 05 06:09 PM
Hallal DavidCEOAug 04Sale196.52612120,270143,516Aug 05 06:09 PM
BELL LEONARDDirectorAug 04Sale196.522,200432,344920,091Aug 05 06:08 PM
Sinha VikasEVP & CFOAug 04Sale196.52675132,651166,646Aug 05 06:08 PM
MACKAY MARTINEVP & Global Head of R&DAug 03Option Exercise130.2943,5005,667,48876,393Aug 05 06:09 PM
MACKAY MARTINEVP & Global Head of R&DAug 03Sale196.5243,5008,548,41832,893Aug 05 06:09 PM
BELL LEONARDDirectorJun 18Sale179.6327,8355,000,001922,291Jun 19 07:09 PM
Moriarty John BEVP & General CounselJun 11Sale170.00914155,38032,428Jun 12 06:26 PM
Monnet DominiqueSVP, Chief Marketing OfficerMay 20Sale162.4025641,5748,787May 22 05:30 PM
MACKAY MARTINEVP & Global Head of R&DMay 14Sale160.334,056650,29832,893May 22 05:30 PM
Islam SaqibEVP, Chief Strat & Port. Off.Apr 27Sale181.576,0321,095,23039,868Apr 30 09:45 PM
BELL LEONARDCEOMar 19Sale188.0715,9523,000,093949,426Mar 20 05:02 PM
MACKAY MARTINEVP & Global Head of R&DMar 02Sale180.3437066,72636,949Mar 03 09:13 PM
Sinha VikasEVP & CFOMar 02Sale180.3448787,826167,321Mar 03 09:13 PM
O'Neill JulieEVP. Global OperationsMar 02Sale180.346,5651,183,93222,090Mar 03 09:13 PM
Islam SaqibEVP, Chief Strat & Port. Off.Mar 02Sale180.3422841,11839,432Mar 03 09:12 PM
Moriarty John BEVP & General CounselMar 02Sale180.3428050,49533,342Mar 03 09:13 PM
BELL LEONARDCEOMar 02Sale180.341,230221,818965,378Mar 03 09:11 PM
Hallal DavidChief Operating OfficerMar 02Sale180.34730131,648132,858Mar 03 09:11 PM
Carmichael ClareEVP, Chief HR OfficerMar 02Sale180.34706127,32027,809Mar 03 09:12 PM
MACKAY MARTINEVP & Global Head of R&DFeb 10Sale173.973,897677,95632,219Feb 12 09:07 PM
Monnet DominiqueSVP, Chief Marketing OfficerFeb 10Sale171.1532555,6245,213Feb 12 09:07 PM
O'Neill JulieEVP. Global OperationsFeb 10Sale171.15795136,06423,555Feb 12 09:07 PM
Sinha VikasEVP & CFOFeb 10Sale171.151,985339,733162,708Feb 12 09:08 PM
BELL LEONARDCEOFeb 10Sale171.155,740982,401944,308Feb 12 09:06 PM
Hallal DavidChief Operating OfficerFeb 10Sale171.151,980338,877124,033Feb 12 09:06 PM
Carmichael ClareEVP, Chief HR OfficerFeb 10Sale171.151,490255,01421,670Feb 12 09:06 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 10Sale171.151,500256,72534,560Feb 12 09:06 PM
Moriarty John BEVP & General CounselFeb 10Sale171.151,490255,01426,777Feb 12 09:07 PM
Sinha VikasEVP & CFOFeb 09Sale174.182,703470,810164,693Feb 09 08:48 PM
Moriarty John BEVP & General CounselFeb 09Sale174.161,455253,40328,267Feb 09 08:48 PM
BELL LEONARDCEOFeb 09Sale173.988,6601,506,667950,048Feb 09 08:46 PM
Hallal DavidChief Operating OfficerFeb 09Sale173.932,920507,876126,013Feb 09 08:46 PM
Carmichael ClareEVP, Chief HR OfficerFeb 09Sale173.751,665289,29423,160Feb 09 08:47 PM
BELL LEONARDCEOFeb 04Sale174.352,223387,583924,718Feb 05 08:10 PM
Carmichael ClareEVP, Chief HR OfficerFeb 04Sale174.3520736,09016,065Feb 05 08:09 PM
Sinha VikasEVP & CFOFeb 04Sale174.37676117,874155,706Feb 05 08:10 PM
Hallal DavidChief Operating OfficerFeb 04Sale174.38608106,023117,243Feb 05 08:10 PM
BELL LEONARDCEOFeb 03Sale174.253,000522,750926,941Feb 05 08:10 PM
Sinha VikasEVP & CFOFeb 03Sale174.06895155,784156,382Feb 05 08:10 PM
Hallal DavidChief Operating OfficerFeb 03Sale174.02765133,125117,851Feb 05 08:10 PM
BELL LEONARDCEODec 18Sale182.0313,7352,500,182929,941Dec 19 04:49 PM
Hallal DavidChief Operating OfficerDec 18Sale182.035,4941,000,073113,122Dec 19 04:49 PM
BELL LEONARDCEODec 17Option Exercise22.9016,680381,972960,356Dec 19 04:49 PM
BELL LEONARDCEODec 17Sale177.8416,6802,966,315943,676Dec 19 04:49 PM
Brennan David RDirectorDec 15Buy186.9950093,4951,268Dec 16 05:18 PM
Moriarty John BEVP & General CounselDec 11Sale195.533,570698,04220,962Dec 15 06:50 PM
Veneman Ann MDirectorDec 11Sale193.031,235238,3923,447Dec 15 06:50 PM
BELL LEONARDCEODec 09Option Exercise22.9016,665381,629960,341Dec 09 07:37 PM
BELL LEONARDCEODec 09Sale199.9416,6653,332,000943,676Dec 09 07:37 PM
BELL LEONARDCEODec 08Option Exercise21.8159,9341,307,1561,003,610Dec 09 07:37 PM
BELL LEONARDCEODec 08Sale198.8859,93411,919,423943,676Dec 09 07:37 PM
BELL LEONARDCEODec 05Option Exercise17.9856,7211,019,8441,000,397Dec 09 07:37 PM
BELL LEONARDCEODec 05Sale197.1256,72111,181,101943,676Dec 09 07:37 PM
Carmichael ClareSVP, Chief HR OfficerDec 04Option Exercise57.0210,000570,20026,272Dec 08 04:59 PM
Carmichael ClareSVP, Chief HR OfficerDec 04Sale196.2510,0001,962,50016,272Dec 08 04:59 PM
KELLER WILLIAM RDirectorDec 04Sale196.255,000981,2507,276Dec 08 04:59 PM
Sinha VikasEVP & CFODec 03Option Exercise19.1550,000957,400212,770Dec 04 05:20 PM
Sinha VikasEVP & CFODec 03Sale198.3650,0009,918,230162,770Dec 04 05:20 PM
Sinha VikasEVP & CFODec 02Option Exercise17.9825,000449,500187,770Dec 04 05:20 PM
Sinha VikasEVP & CFODec 02Sale200.1625,0005,004,000162,770Dec 04 05:20 PM